Health Care • Biotechnology: Pharmaceutical Preparations
$431.70 ▲ +0.70
(+0.16%)
MKT CAP: $9.97B • VOL: 268.0K
52W L $399 52W H $615
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$363
MEDIAN
$484
MEAN
$492
HIGH
$587
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MDGL TAPE
MDGL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $522.36 | $496.45 | 2025-02-14 | $392.85 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $543.94 | $509.41 | 2025-02-06 | $405.80 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $492.14 | $474.87 | 2025-01-29 | $414.43 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $440.33 | — | 2025-01-17 | $423.07 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $379.90 | $410.11 | 2025-01-09 | $384.21 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $513.72 | $448.97 | 2024-12-18 | $375.58 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $418.75 | $436.02 | 2024-12-04 | $401.48 | -4.3% | 48% | C |